Video: Plan your schedule now for #AHA21

Be sure to start your calendar of events for Scientific Sessions with this lineup of groundbreaking late-breaking science results.

LBS.01 | Valves, Veins and New Viewpoints in Cardiothoracic Surgery | 9:30-10:30 a.m. EST, Saturday, Nov. 13

  • Aortic Valve Replacement Versus Watchful Waiting in Asymptomatic Severe Aortic Stenosis: The Avatar Trial (AVATAR)
  • Evaluating the Benefit of Concomitant Tricuspid Repair During Mitral Valve Surgery
  • A Randomized Study of Early Versus Standard Coronary Artery Bypass Surgery Among Patients Presenting With Acute Coronary Syndromes Treated With Ticagrelor (RAPID CABG)
  • Efficacy and Safety of an External Support Device for Saphenous Vein Coronary Bypass Grafts: The VEST Trial (VEST) 

LBS.02 | Hypertension: Local, Global and Pandemic Impacts | 3-4 p.m. EST, Saturday, Nov. 13

  • A Remotely Delivered Hypertension and Lipid Program in 10,000 Patients Across a Diverse Health Care Network
  • Disruption in Blood Pressure Control With the COVID-19 Pandemic: A Study of 24 U.S. Health Systems in the PCORnet Blood Pressure Control Laboratory (BP Track)
  • A Cluster Randomized Trial of a Village Doctor-Led Intervention on Blood Pressure Control: China Rural Hypertension Control Project (CRHCP)

LBS.03 | Prevention to Intervention in Atrial Arrhythmias 8-9 a.m. EST, Sunday, Nov. 14

  • The Coffee and Real-Time Atrial and Ventricular Ectopy (CRAVE) Trial (CRAVE)
  • Dabigatran Versus Warfarin on Cognitive Outcomes in Nonvalvular Atrial Fibrillation: Results of the GIRAF Trial. (GIRAF)
  • Posterior Left Pericardiotomy Reduces Postoperative Atrial Fibrillation After Cardiac Surgery (PALACS)
  • Outcomes of Adjunctive Left Atrial Appendage Ligation Utilizing the LARIAT Compared to Pulmonary Vein Antral Isolation Alone: The AMAZE Trial (AMAZE)

LBS.04 | Information Overload? Striving to Improve Care Delivery Through Digital Health and Automated Data | 2:45-3:45 p.m. EST, Sunday, Nov. 14

  • Risk Evaluation and its Impact on Clinical Decision-Making and Outcomes in Heart Failure: The REVeAL-HF Trial (REVeAL-HF)
  • Detection of Atrial Fibrillation in a Large Population Using Wearable Devices: The Fitbit Heart Study         
  • Testing Individualized Triggers of Atrial Fibrillation: A Randomized Controlled Trial (I-STOP-AFib)

LBS.05 | Building on the Foundations of Treatment: Advances in Heart Failure Therapy | 4-5 p.m. EST, Sunday, Nov. 14

  • Empagliflozin in Heart Failure With a Preserved Ejection Fraction ≥50% — Results From the EMPEROR-Preserved Clinical Trial   (EMPEROR-Preserved)
  • The Canagliflozin Impact on Health Status, Quality of Life and Functional Status in Heart Failure (CHIEF-HF) Clinical Trial (CHIEF-HF)
  • Efficacy and Safety of Empagliflozin in Hospitalized Heart Failure Patients: Main Results From the EMPULSE Trial (EMPULSE)
  • Randomized Trial of Targeted Transendocardial Delivery of Mesenchymal Precursor Cells in High-Risk Chronic Heart Failure Patients With Reduced Ejection Fraction (DREAM-HF)

LBS.06 | Fish Oil, Cocoa and Cholesterol: Recipes for CVD Prevention? | 8-9 a.m. EST, Monday, Nov. 15

  • Icosapent Ethyl Versus Placebo in Outpatients With COVID-19: The Main Results of PREPARE-IT 2 (PREPARE-IT 2)
  • The Clinical Safety, Pharmacokinetics and LDL-Cholesterol Lowering Efficacy of MK-0616, an Oral PCSK9 Inhibitor 

LBS.07 | New Drugs and New Drug Indications in Cardiovascular Disease | 11 a.m.-Noon EST, Monday, Nov. 15

  • Effects of Aspirin on Dementia and Cognitive Impairment in the ASCEND Trial (ASCEND)
  • P2y12 Inhibitors in Noncritically Ill Hospitalized Patients With Covid-19 (ACTIV-4A)
  • Effect Of Bentracimab on Platelet Inhibition and Hemostasis in Ticagrelor Patients With Uncontrolled Hemorrhage or Requiring Urgent Surgery in the REVERSE-IT (REVERSE-IT)
  • Milvexian for Prevention of Venous Thromboembolism After Elective Knee Arthroplasty: The AXIOMATIC-TKR Study (AXIOMATIC-TKR)